The mission of the Rutgers Cancer Institute of New Jersey (CINJ) is to reduce the burden of cancer by advancing cancer research, prevention, screening, education and care for one of the nation?s most diverse and densely populated states, as well as the broader nation. To accomplish this mission, the CINJ Director, Steven K. Libutti, MD, works closely with the rest of the CINJ Senior Leadership team, which includes the Deputy Director (Eileen White), and Associate Directors for Clinical Research (Howard S. Hochster), Basic Research (Eileen White), Cancer Prevention, Control and Population Research (Sharon L. Manne), Translational Research (Shridar Ganesan), Consortium Research (Yibin Kang), Research and Education Affairs (Edmund C. Lattime), Administration and Planning (Linda L. Tanzer) and Community Outreach and Engagement (new, Manne interim). Implementation of a five-year Strategic Plan (2015-2020) was underway at the time of Libutti?s arrival in 2017; the plan was re-assessed modified to represent the new Director?s vision. The Internal Advisory Board (includes the Chancellor, Deans and other leaders at Rutgers and Princeton Universities) and the External Advisory Board reviewed these proposed modifications and provided critical input and guidance. This oversight and leadership structure proved its effectiveness with the transition to a new Director; the major goals of the strategic plan were affirmed, with significant and sustained progress made toward accomplishing them, and new initiatives important to the Director?s vision were seamlessly integrated. Despite the change in Directorship, senior leaders did not lose momentum and achieved important strategic accomplishments, including: restructured and enhanced precision medicine initiative; recruitment of a new Associate Director for Clinical Research; increased accruals to interventional studies; creation of an Office of Community Outreach and Engagement and launch of a search for an Associate Director to oversee these efforts; expansion of the Metabolomics shared resource (jointly managed with Princeton University) and launch of two new developing shared resources for Small Molecule Screening (with Princeton) and Immune Monitoring; expansion of educational programs and successful management of major statewide retreats and conferences; launch of a new colon and lung cancer screening initiative for underserved regions of CINJ?s catchment area; and enhancement and strengthening of the consortium with Princeton University through the creation and appointment of an Associate Director for Consortium Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-20
Application #
9632910
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890
Llanos, Adana A M; Tsui, Jennifer; Rotter, David et al. (2018) Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women. BMC Womens Health 18:162
Hadigol, Mohammad; Khiabanian, Hossein (2018) MERIT reveals the impact of genomic context on sequencing error rate in ultra-deep applications. BMC Bioinformatics 19:219
Severson, Eric A; Riedlinger, Gregory M; Connelly, Caitlin F et al. (2018) Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131:2501-2505
Shih, Weichung Joe; Lin, Yong (2018) Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Stat Med 37:687-709
Ding, Qiang; Gaska, Jenna M; Douam, Florian et al. (2018) Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc Natl Acad Sci U S A 115:E6310-E6318
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Modi, Parth K; Wang, Ye; Kirk, Peter S et al. (2018) The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 117:50-56
Dai, Zhuqing; Feng, Simin; Liu, Anna et al. (2018) Anti-inflammatory effects of newly synthesized ?-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice. Food Res Int 109:350-357

Showing the most recent 10 out of 775 publications